Literature DB >> 33860177

Set and Setting: A Randomized Study of Different Musical Genres in Supporting Psychedelic Therapy.

Justin C Strickland1, Albert Garcia-Romeu1, Matthew W Johnson1.   

Abstract

Mounting evidence supports the serotonin 2A receptor agonist psilocybin as a psychiatric pharmacotherapy. Little research has experimentally examined how session "set and setting" impacts subjective and therapeutic effects. We analyzed the effects of the musical genre played during sessions of a psilocybin study for tobacco smoking cessation. Participants (N = 10) received psilocybin (20-30 mg/70 kg) in two sessions, each with a different musical genre (Western classical versus overtone-based), with the order counterbalanced. Participants chose one genre for a third session (30 mg/70 kg). Mystical experiences scores tended to be higher in overtone-based sessions than in Western classical sessions. Six of ten participants chose the overtone-based music for a third session. Biologically confirmed smoking abstinence was similar based on musical choice, with a slight benefit for participants choosing the overtone-based playlist (66.7% versus 50%). These data call into question whether Western classical music typically used in psychedelic therapy holds a unique benefit. Broadly, we call for experimentally examining session components toward optimizing psychedelic therapeutic protocols.
© 2020 American Chemical Society.

Entities:  

Year:  2020        PMID: 33860177      PMCID: PMC8033606          DOI: 10.1021/acsptsci.0c00187

Source DB:  PubMed          Journal:  ACS Pharmacol Transl Sci        ISSN: 2575-9108


  24 in total

1.  Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.

Authors:  Frederick S Barrett; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2015-10-06       Impact factor: 4.153

2.  Cut-off levels for breath carbon monoxide as a marker for cigarette smoking.

Authors:  Martin A Javors; John P Hatch; Richard J Lamb
Journal:  Addiction       Date:  2005-02       Impact factor: 6.526

Review 3.  Clinical considerations in study designs that use cotinine as a biomarker.

Authors:  Steven L Bramer; Beatrice A Kallungal
Journal:  Biomarkers       Date:  2003 May-Aug       Impact factor: 2.658

Review 4.  Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions.

Authors:  Albert Garcia-Romeu; William A Richards
Journal:  Int Rev Psychiatry       Date:  2018-11-13

5.  Activation of 5-HT2A/C receptor reduces glycine receptor-mediated currents in cultured auditory cortical neurons.

Authors:  Bin Luo; Lingli Hu; Chunhua Liu; Yiping Guo; Haitao Wang
Journal:  Amino Acids       Date:  2015-09-14       Impact factor: 3.520

Review 6.  Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.

Authors:  Matthew W Johnson; Peter S Hendricks; Frederick S Barrett; Roland R Griffiths
Journal:  Pharmacol Ther       Date:  2018-12-04       Impact factor: 12.310

7.  Long-term follow-up of psilocybin-facilitated smoking cessation.

Authors:  Matthew W Johnson; Albert Garcia-Romeu; Roland R Griffiths
Journal:  Am J Drug Alcohol Abuse       Date:  2016-07-21       Impact factor: 3.829

8.  Breath carbon monoxide as an indication of smoking habit.

Authors:  E T Middleton; A H Morice
Journal:  Chest       Date:  2000-03       Impact factor: 9.410

9.  Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.

Authors:  Matthew W Johnson; Albert Garcia-Romeu; Mary P Cosimano; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2014-09-11       Impact factor: 4.153

Review 10.  Psychedelics.

Authors:  David E Nichols
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

View more
  8 in total

Review 1.  Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation.

Authors:  Matthew W Johnson
Journal:  Curr Top Behav Neurosci       Date:  2022

Review 2.  Effects of Setting on Psychedelic Experiences, Therapies, and Outcomes: A Rapid Scoping Review of the Literature.

Authors:  Tasha L Golden; Susan Magsamen; Clara C Sandu; Shuyang Lin; Grace Marie Roebuck; Kathy M Shi; Frederick S Barrett
Journal:  Curr Top Behav Neurosci       Date:  2022

Review 3.  Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective.

Authors:  John R Kelly; Claire M Gillan; Jack Prenderville; Clare Kelly; Andrew Harkin; Gerard Clarke; Veronica O'Keane
Journal:  Front Psychiatry       Date:  2021-12-17       Impact factor: 4.157

Review 4.  Psychedelics and Other Psychoplastogens for Treating Mental Illness.

Authors:  Maxemiliano V Vargas; Retsina Meyer; Arabo A Avanes; Mark Rus; David E Olson
Journal:  Front Psychiatry       Date:  2021-10-04       Impact factor: 4.157

5.  Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report.

Authors:  Drummond E-Wen McCulloch; Maria Zofia Grzywacz; Martin Korsbak Madsen; Peter Steen Jensen; Brice Ozenne; Sophia Armand; Gitte Moos Knudsen; Patrick MacDonald Fisher; Dea Siggaard Stenbæk
Journal:  Front Pharmacol       Date:  2022-03-09       Impact factor: 5.810

6.  Classic Psychedelic Drugs: Update on Biological Mechanisms.

Authors:  Franz X Vollenweider; John W Smallridge
Journal:  Pharmacopsychiatry       Date:  2022-01-25       Impact factor: 2.544

Review 7.  The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice.

Authors:  Cindy A Stein; Andrew Penn; Stephanie Van Hope; Caroline G Dorsen; Mariavittoria Mangini
Journal:  J Midwifery Womens Health       Date:  2022-05-06       Impact factor: 2.891

8.  Ceremonial Ayahuasca in Amazonian Retreats-Mental Health and Epigenetic Outcomes From a Six-Month Naturalistic Study.

Authors:  Simon G D Ruffell; Nige Netzband; WaiFung Tsang; Merlin Davies; Matthew Butler; James J H Rucker; Luís Fernando Tófoli; Emma Louise Dempster; Allan H Young; Celia J A Morgan
Journal:  Front Psychiatry       Date:  2021-06-09       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.